Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” Journal of Palliative Medicine, August 2023.
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. “Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.” International Review of Psychiatry, May 2024.
Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. “Adverse Events Should Not Be Surprising in Psychedelic Research.” Psychedelic Medicine, September 2024.
Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
Agrawal M., Emanuel E., Jenkins B., et al. “Long-term Benefits of Single-Dose Psilocybin in Depressed Cancer Patients.” Cancer, June 2025.
Rosa, W.E., Napolitano, S., McAndrew, N.S., Jenkins, B., et al. “Meaning-centered psychotherapy for psilocybin-assisted therapy among patients with advanced cancer and major depression: Rationale and preliminary evaluation of MCP-PSIL.” Psychedelic Medicine, August 2025.
Tarbi, E. C., Miner, S. A., Nigam, K., et al. “To have the encounter with our own finiteness in that existential way”: Descriptions of existential experience in patients with cancer and major depression participating in psilocybin-assisted group therapy. Psychedelic Medicine, August 2025. #2
The clinic does an excellent job at educating the participant about what they can do to get the most out of the experience.
An overview of DMT, how it works, and why researchers are studying its potential role in mental health care.
Learn more about how Sunstone Therapies approaches psychedelic-assisted therapy.
Whether or not a clinical trial is right for you, understanding your options is an important first step.
Research suggests that psychedelic-assisted therapy may offer meaningful benefits when delivered within a medical framework.
Learn what clinical trial participation involves and whether it aligns with your needs, goals, and circumstances.
Public Television audiences will gain a closer look at psychedelic-assisted therapy, an emerging area in mental health treatments, and how it is being implemented within structured clinical care in an upcoming segment of All Access with Andy Garcia.
Discover how our comprehensive care model protects both physical and psychological well-being.
Continuous informed consent, psychological safety, and individualized care are built into every step of the treatment process.
Sunstone Therapies is enrolling for a study of psilocybin therapy for women with sexual assault-related PTSD.
Sunstone Therapies has launched a new clinical trial evaluating group MDMA-assisted therapy for veterans living with PTSD. Supported by funding from the State of Maryland and Reason for Hope, the study will compare individual and group therapy models to assess safety, feasibility, and scalability. The research aims to expand access to evidence-based mental health care for veterans while generating critical insights into how psychedelic-assisted therapy may be delivered more effectively in the future.
Sunstone’s newest IIT offers veterans with PTSD access to breakthrough MDMA-assisted therapy research in both group and individual formats.
As psychedelic-assisted therapies continue advancing through clinical research, understanding how they fit within existing mental health care systems is increasingly important.
What happens when an oncologist and a mortician discuss the mystery of death? Dr. Manish Agrawal joins the Death And podcast to bridge the gap between clinical rigor and human mystery. From the “collusion of denial” to the “infinity” found between birth and death, discover how psychedelic-assisted care invites patients back into their own experience to find peace and connection.
Dr. Manish Agrawal, CEO of Sunstone Therapies, joined Great Day Washington to discuss adjustment disorder—a common but frequently overlooked emotional response to serious illnesses like cancer, MS, and Parkinson’s. While modern medicine excels at treating physical symptoms, Dr. Agrawal highlights the “collusion of denial” that often leaves patients to navigate emotional upheaval in silence. Learn how Sunstone is addressing this critical gap through the REKINDLE Phase 2 study, an innovative clinical trial evaluating an investigational treatment for psychological distress in patients facing life-altering diagnoses.
Why veterans’ trauma requires new therapeutic approaches.
National Geographic recently highlighted emerging research on psilocybin-assisted therapy for patients facing advanced cancer and end-of-life distress. The article explores how psychedelic-assisted therapy may help reduce depression, anxiety, and existential suffering when delivered within structured clinical settings.
We are setting the industry standard for high quality training for mental health professionals in psychedelic therapy research.
New findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression.
Blending Science, Story, and the Human Side of Healing October, 2025 — Sunstone Therapies CEO Dr. Manish Agrawal joined Dan […]
This clinical trial will explore whether psilocybin is more effective than an active placebo and if two doses are better than one.
A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
In psychedelic therapy clinical research, setting clear expectations is paramount.
Co-founder and CEO, Dr. Manish Agrawal, recently shared his expertise and vision for the future of psychedelic-assisted therapy in oncology in a four-part interview series with Pharmacy Times’ Lead Editor, Alana Hippensteele.
Sunstone is pleased to begin enrollment of two clinical studies exploring the therapeutic potential of DMT (N,N-dimethyltryptamine) and its analogs.
June 16, 2025 | A new study conducted by Sunstone Therapies suggests that a single dose of psilocybin, combined with psychological support, can provide sustained relief from depression for some cancer patients.
Manish Agrawal, MD, brings an extensive academic, clinical, and research background and depth of experience to Sunstone.
Kimberly Roddy, MBA, Co-Founder and COO of Sunstone Therapies Kimberly Roddy is the Co-Founder and Chief Operations Officer of Sunstone […]
Psychedelic therapy can helps patients face difficult emotions with curiosity, supporting deep healing and lasting change.
Sunstone cofounders spoke with Josh Hardman about what they’ve learned from delivering hundreds of psychedelic therapy sessions.
Psychedelic Medicine–History and Clinical Research January 30, 2025 Psychedelic Medicine: History and Clinical Research explores the resurgence of psychedelics in […]
Manish Agrawal, MD joins Living Medicine host, Dr. Sandra Newes to discuss the challenges and future of psychedelic-assisted therapy research.
Manish Agrawal, MD joins Power to the Patient host Brandon Li to discuss the transformative role of psychedelics in cancer care and mental health.
Psychedelic-assisted therapies may be a promising treatment for combat related moral injury.
Dr. Manish Agrawal appointed to serve on Maryland’s Task Force on Responsible Use of Natural Psychedelic Substances.
Psychedelic-assisted therapies bring a critical new dimension to questions about subjectivity in psychiatry.
Psychedelic-assisted therapies bring a critical new dimension to questions about subjectivity in psychiatry.
September, 2024 Dear Sunstone Community, It has been a pivotal couple of weeks for the field of psychedelic-assisted therapy (PAT) […]
Psychedelic-assisted therapies bring a critical new dimension to questions about subjectivity in psychiatry.